PQ Submission definition

PQ Submission means a Bidder's response to the PQ Documentation.
Sample 1Sample 2Sample 3
PQ Submission means the Respondent's submission to the Pre-Qualification.
Sample 1Sample 2Sample 3
PQ Submission means a Bidder's response to the PQ Document;
Sample 1

Examples of PQ Submission in a sentence

  • Applicable exchange rates for the year 2020 will be published at least 30 days prior to the PQ Submission Date and shall reflect the most updated information known on such publication date.

  • Failure of the Participant to examine the Invitation and any of its terms shall not release the Participant from its obligations pursuant to Invitation and full compliance with its PQ Submission.

  • Without derogating from the generality of the provisions of Regulation 21(e) of the Mandatory Tenders Regulations, 5753-1993 (the "Regulations") (and the discretion granted thereunder to the IAA), the Participants are required to detail, within the PQ Statement Form, in a clear, complete and legible manner, all information contained in their PQ Submission, which they consider to be confidential.

  • Bidder Any person or Bidder Group that makes a PQ Submission or an EPQ Submission, a Qualifying Bidder, a Preferred Bidder or a Successful Bidder (as applicable).

  • The PQ Submission and all supporting technical and financial data and other documentation to be submitted by the Applicant must be written in the English language.

  • If the Applicant is a consortium, then the assessment of the PQ criteria will extend to each member of the consortium and the Applicant must indicate in its PQ Submission who will be the leader of the consortium and each member's commitment to the Project.

  • However, intellectual property in the information which originates from the Applicant and contained in the PQ Submission submitted by the Applicant shall remain vested in the Applicant.

  • The completed form is to be handed over to the Applicant in a sealed envelope for submission by the Applicant as part of its PQ Submission if the Applicant is provided with credit facilities by the Bank or Financial Institution) To:MALAYSIA AIRPORTS HOLDINGS BERHAD,Malaysia Airports Corporate Office, Persiaran Korporat KLIA,64000 KLIA Sepang,Selangor Darul Ehsan, Malaysia Name of Firm: ………………………………….....................................................

  • An Applicant must ensure that its PQ Submission is in accordance with the requirements of the PQD and provide all information and documents required to be submitted under the PQD as part of its PQ submission.

  • If the Applicant or a consortium member is a limited liability company, then its PQ Submission shall also include identification of its shareholders.

Related to PQ Submission

  • Regulatory Submissions means any filing, application or submission with any Regulatory Authority, including authorizations, approvals or clearances arising from the foregoing, including Regulatory Approvals and any pricing or reimbursement approvals, as applicable, and all correspondence or communication with or from the relevant Regulatory Authority, as well as minutes of any material meetings, telephone conferences or discussions with the relevant Regulatory Authority, in each case, with respect to a Licensed Product.

  • Electronic Submission means a successful submittal of Offeror’s proposal.

  • Selected submission means and refers to the submission sent to the City of Waco by the Selected Firm.

  • Approval Application means a BLA, NDA or similar application or submission for a Product filed with a Regulatory Authority in a country or group of countries to obtain marketing approval for a biological or pharmaceutical product in that country or group of countries.

  • Regulatory Filing means any documentation comprising or relating to or supporting any filing or application with any Regulatory Authority with respect to the Licensed Product, including any documents submitted to any Regulatory Authority, including INDs, Regulatory Approval Applications, and all correspondence with any Regulatory Authority with respect to any Licensed Product (including minutes of any meetings, telephone conferences, or discussions with any Regulatory Authority).

  • Regulatory Approval Application means any application submitted to an appropriate Regulatory Authority seeking any Regulatory Approval.

  • Planning Submission or “CAPS” or “Community Accountability Planning Submission” means the HSP Board approved planning document submitted by the HSP to the Funder. The form, content and scheduling of the Planning Submission will be identified by the Funder;

  • FDA means the United States Food and Drug Administration and any successor agency thereto.

  • NDA means a New Drug Application, as defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any corresponding foreign application, registration or certification.

  • Drug Approval Application means an application for Regulatory Approval required before commercial sale or use of a Product as a drug in a regulatory jurisdiction.

  • Marketing Approval Application or “MAA” means a New Drug Application (or its equivalent), as defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any corresponding or similar application, registration or certification in any country.

  • IND means (a) an Investigational New Drug Application as defined in the FD&C Act and applicable regulations promulgated thereunder by the FDA, or (b) the equivalent application to the equivalent agency in any other regulatory jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction.

  • Application Review Start Date means the later date of either the date on which the District issues its written notice that the Applicant has submitted a completed Application or the date on which the Comptroller issues its written notice that the Applicant has submitted a completed Application and as further identified in Section 2.3.A of this Agreement.

  • Regulatory Materials means regulatory applications, submissions, notifications, communications, correspondence, registrations, Regulatory Approvals or other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, Manufacture, or Commercialize a Licensed Product in a particular country or jurisdiction.

  • DMF means a drug master file, as provided for in 21 CFR § 314.420 or similar submission to or file maintained with the FDA or other Governmental Authority or Regulatory Authority that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs.

  • Third-party filer means an entity that submits a Product filing to the Commission on behalf of an Insurer.

  • BLA means a Biologics License Application under the United States’ Public Health Services Act and Federal Food, Drug and Cosmetics Act, each as amended, and the regulations promulgated thereunder, or a comparable filing seeking Regulatory Approval in any country.

  • Regulatory Filings means any and all regulatory applications, filings, approvals and associated correspondence required to Develop, manufacture, market, sell and import Products in, or into, each country or jurisdiction in the Territory.

  • Marketing Authorization Application or “MAA” means an application to the appropriate Regulatory Authority for approval to sell the Product (but excluding Pricing Approval) in any particular country or regulatory jurisdiction.

  • Program of study means a curriculum that requires a candidate to demonstrate and document competency in the specific knowledge, skills, and dispositions for a particular endorsement to an educator’s license, a licensure content area, or level of licensure, and is:

  • Progress Report Form means UN Women’s standard form for progress reports attached to this Agreement.

  • Clinical Study means a Xxxxx 0 Xxxxx, Xxxxx 2 Study, Phase 3 Study, Post-Marketing Study, Supplemental Study or other study (including a non-interventional study) in humans to obtain information regarding the product, including information relating to the safety, tolerability, pharmacological activity, pharmacokinetics, dose ranging or efficacy of the product.

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.

  • Third Party Applications means online, Web-based applications and offline software products that are provided by third parties and are identified as third-party applications, including but not limited to those listed on the AppExchange and the Reseller Application.

  • Development Application means the development application identified in Item 5 of Schedule 1 and includes all plans, reports models, photomontages, material boards (as amended supplemented) submitted to the consent authority before the determination of that Development Application.

  • JDC has the meaning set forth in Section 3.2.